ex vivo IL2RG stem cell-based gene therapy (Genethon/University College London/Hannover Medical School)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameex vivo IL2RG stem cell-based gene therapy (Genethon/University College London/Hannover Medical School)
Drug Alias NameG2SCID lentiviral vector transduced CD34+ cellsex vivo IL2RG-transduced hematopoietic stem precursor cell therapy (Genethon/University College London/Hannover Medical School)lentiviral gene therapy (Genethon/University College London/Hannover Medical School)lentiviral gene therapy (Genethon/UCL/Hannover Medical School)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionIL-2RG gene transference
TargetsInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsSevere Combined Immunodeficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited KingdomFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenethon
China Registration ClassN/A

Develop Information

Active CompaniesMedizinische Hochschule HannoverGenethonUniversity College London
Inactive CompaniesN/A
Active IndicationsSevere Combined Immunodeficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A